128 related articles for article (PubMed ID: 37553920)
1. Diagnostic Importance of PAX2, ARID1A, and FOXA1 Biomarkers in Atypical Endometrial Hyperplasia.
Yildiz ON; Topal CS; Zemheri IE
J Coll Physicians Surg Pak; 2023 Aug; 33(8):847-851. PubMed ID: 37553920
[TBL] [Abstract][Full Text] [Related]
2. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
3. Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.
Aguilar M; Chen H; Rivera-Colon G; Niu S; Carrick K; Gwin K; Cuevas IC; Sahoo SS; Li HD; Zhang S; Zheng W; Lucas E; Castrillon DH
Am J Surg Pathol; 2022 Mar; 46(3):404-414. PubMed ID: 34545858
[TBL] [Abstract][Full Text] [Related]
4. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
Joiner AK; Quick CM; Jeffus SK
Int J Gynecol Pathol; 2015 Jan; 34(1):40-6. PubMed ID: 25473752
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.
Trabzonlu L; Muezzinoglu B; Corakci A
Pathol Oncol Res; 2019 Apr; 25(2):471-476. PubMed ID: 29270778
[TBL] [Abstract][Full Text] [Related]
6. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.
Raffone A; Travaglino A; Saccone G; Mascolo M; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):287-299. PubMed ID: 30511741
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer.
Raffone A; Travaglino A; Saccone G; Cieri M; Mascolo M; Mollo A; Insabato L; Zullo F
APMIS; 2019 Sep; 127(9):597-606. PubMed ID: 31237034
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of PAX2 in hyperplastic and malignant endometrium.
Kahraman K; Kiremitci S; Taskin S; Kankaya D; Sertcelik A; Ortac F
Arch Gynecol Obstet; 2012 Jul; 286(1):173-8. PubMed ID: 22274645
[TBL] [Abstract][Full Text] [Related]
9. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment: A Longitudinal Study.
Chen H; Lucas E; Strickland AL; Carrick K; Gwin K; Castrillon DH; Rivera-Colon G; Niu S; Molberg KH; Zheng W
Am J Surg Pathol; 2020 Oct; 44(10):1429-1439. PubMed ID: 32931681
[TBL] [Abstract][Full Text] [Related]
10. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia.
Hahn HS; Chun YK; Kwon YI; Kim TJ; Lee KH; Shim JU; Mok JE; Lim KT
Eur J Obstet Gynecol Reprod Biol; 2010 May; 150(1):80-3. PubMed ID: 20185225
[TBL] [Abstract][Full Text] [Related]
11. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
[TBL] [Abstract][Full Text] [Related]
12. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
13. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
[TBL] [Abstract][Full Text] [Related]
14. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
Monte NM; Webster KA; Neuberg D; Dressler GR; Mutter GL
Cancer Res; 2010 Aug; 70(15):6225-32. PubMed ID: 20631067
[TBL] [Abstract][Full Text] [Related]
15. Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia.
Laas E; Ballester M; Cortez A; Gonin J; Canlorbe G; Daraï E; Graesslin O
Gynecol Endocrinol; 2015 Apr; 31(4):282-5. PubMed ID: 25495249
[TBL] [Abstract][Full Text] [Related]
16. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
Trimble CL; Kauderer J; Zaino R; Silverberg S; Lim PC; Burke JJ; Alberts D; Curtin J
Cancer; 2006 Feb; 106(4):812-9. PubMed ID: 16400639
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
Rakha E; Wong SC; Soomro I; Chaudry Z; Sharma A; Deen S; Chan S; Abu J; Nunns D; Williamson K; McGregor A; Hammond R; Brown L
Am J Surg Pathol; 2012 Nov; 36(11):1683-90. PubMed ID: 23073327
[TBL] [Abstract][Full Text] [Related]
18. Risk of coexisting endometrial carcinoma in case of atypical endometrial hyperplasia diagnosed on total hysteroscopic resection.
Pivano A; Crochet P; Carcopino X; Cravello L; Boubli L; Agostini A
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():210-3. PubMed ID: 27343737
[TBL] [Abstract][Full Text] [Related]
19. PAX2 and cyclin D1 expression in the distinction between cervical microglandular hyperplasia and endometrial microglandular-like carcinoma: a comparison with p16, vimentin, and Ki67.
Stewart CJ; Crook ML
Int J Gynecol Pathol; 2015 Jan; 34(1):90-100. PubMed ID: 25473758
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia.
Merisio C; Berretta R; De Ioris A; Pultrone DC; Rolla M; Giordano G; Tateo S; Melpignano M
Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):107-11. PubMed ID: 16154046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
